https://www.dailypharm.com/user/news/343889
[데일리팜]수요 폭발 '소아 근시' 시장, 하루 한 방울 억제제 등장
식품의약품안전처가 최근 소아 근시 진행을 억제하는 저농도 아트로핀 점안제 완제품을 연이어 허가하면서 그동안 병·의원 원내 조제와 드림렌즈에 머물렀던 국내 소아 근시 치료 시장이 정식
www.dailypharm.com
Driven by
the Ministry of Food and Drug Safety's
approval of low-concentration
atropine eye drops on
October 23 and 26, 2023,
the pediatric myopia
treatment market is
undergoing a reorganization.
With the increasing use of
digital devices elevating
the risk of pediatric myopia,
demand for treatment
among parents is surging,
growing the need for
prescription drugs with
proven safety.
The low-concentration
atropine eye drop market
is expected to expand
going forward,
which is anticipated to
enhance treatment safety
and effectiveness
for pediatric patients.
댓글